Herbalife (HLF) Q3 2025 earnings review
Revenue Turns the Corner, but Profitability Lags Behind
Herbalife reported a significant strategic milestone, with Q3 Net Sales growing 2.7% YoY, marking a reversal after six quarters of declines. The highlight was the North America segment, which returned to growth (+1.0% YoY) for the first time since Q2 2021, validating management's turnaround efforts. However, this top-line recovery has not yet translated to the bottom line. Adjusted EBITDA declined 2% YoY to $163M, and Adjusted EPS fell to $0.50 from $0.57, pressured by FX headwinds and a higher tax rate. While guidance for Q4 suggests accelerating sales growth, the implied profitability remains flat, indicating the path to a full recovery is still underway.
🐂 Bull Case
The return to growth in North America (+1.0%) for the first time in over four years is a critical proof point that the company's foundational rebuilding efforts and distributor engagement initiatives are yielding tangible results.
Continued focus on debt reduction has lowered the total leverage ratio to 2.8x, beating the company's own 3.0x target. The full repayment of the 2025 senior notes de-risks the balance sheet, with no significant maturities until 2028.
The Pro2col digital platform beta is scaling with 7,900 distributors, showing strong early engagement. This, combined with personalized supplement capabilities from Link BioScience, forms a clear, long-term technology-driven growth story.
🐻 Bear Case
The return to sales growth did not flow through to profits, with Adjusted EBITDA margin compressing 60 bps YoY to 12.8%. Q4 guidance implies this trend will continue, raising questions about pricing power and cost control.
Contradicting the positive narrative, worldwide new distributor growth turned negative, declining 2% YoY. This reverses three consecutive quarters of growth and is a worrying leading indicator for future sales momentum.
The China segment continues to struggle, with sales declining another 4.7% YoY. While management frames this as a strategic transition, the region remains a persistent headwind to overall corporate performance.
⚖️ Verdict: ⚪
Mixed. The revenue turnaround, particularly in North America, is a significant and hard-won victory that cannot be understated. However, the positive top-line story is offset by the simultaneous decline in profitability and a reversal in worldwide new distributor growth. The company is successfully navigating the first part of its turnaround but now faces the more difficult challenge of converting sales into sustainable profit growth.
Key Themes
North America Turnaround Validates Strategy
After more than four years of declines, North America's return to 1.0% YoY sales growth is the most important positive development. Management credits nearly two years of foundational work, renewed recruiting efforts, and new technology. New distributor growth in the region was a very strong +17% YoY. This inflection point suggests the company's most challenged market has finally stabilized and is beginning to recover.
New Distributor Growth Reverses, Flashing a Warning Sign
A key data point that contradicts the optimistic narrative is the -2% YoY decline in new distributors joining worldwide. This marks a reversal from three prior quarters of strong growth (+14% in 24Q3, +22% in 24Q4, +16% in 25Q1) and is a critical leading indicator. While management highlights a 2-year stacked growth of 11%, the recent negative turn raises concerns about the sustainability of the sales recovery if the recruiting pipeline weakens.
Digital Transformation (Pro2col) Moves Forward
Herbalife is aggressively pushing its transition to a tech-enabled wellness platform. The beta for its Pro2col app has scaled to 7,900 distributors and is showing strong engagement, with users logging millions of steps and scheduling hundreds of thousands of product uses. The company expanded beta access to retail customers and is planning a full commercial launch in the U.S. by year-end, positioning it as a key driver for 2026.
Margin Compression and Profit Lag
Despite higher sales, profitability metrics weakened. Adjusted EBITDA margin fell 60 bps YoY to 12.8%, and Q4 guidance implies the metric will remain under pressure. Management cited the non-repeat of a $5M China government grant and an $8M FX headwind on Adjusted EPS. This demonstrates that the company's pricing power and operational efficiency are not yet sufficient to drive operating leverage on the recovering sales.
Aggressive Deleveraging Strengthens Financial Foundation
The company continues to execute its capital allocation priority of debt reduction. It fully repaid the remaining $147M on its 2025 Senior Notes and reduced its total leverage ratio to 2.8x, well ahead of its year-end goal of 3.0x. This financial discipline provides significant stability and flexibility as it invests in its strategic transformation.
Product Innovation Accelerates with AI-Powered Skincare
The launch of HL/Skin, a K-beauty skincare line, in EMEA demonstrates increased agility, moving from concept to market in just 11 months. The product is supported by an AI-powered skin assessment tool that provides personalized analysis and product recommendations, aligning the company's product strategy with its broader push into technology and personalization.
Other KPIs
Stable. The ratio improved sequentially from 3.0x in Q2 and significantly from 3.3x a year ago. The company achieved its year-end target of 'below 3.0x' a quarter early, underscoring its commitment to de-risking the balance sheet and its strong cash generation.
Up 40% from $99.5 million in Q3 2024. The strong cash generation, even as sales have just started to recover, highlights healthy working capital management and the underlying cash-generative nature of the business model, which is critical for funding debt repayments and strategic investments.
Down 60 bps YoY from 78.3%. According to management, pricing benefits of 80 bps were more than offset by a 90 bps headwind from foreign currency and 30 bps from input cost inflation. This clearly quantifies the material impact FX is having on profitability.
Guidance
Accelerating. The midpoint of +3.5% implies an acceleration from the +2.7% growth reported in Q3. This suggests management has confidence that the sales turnaround is gaining momentum into year-end.
Stable/Decelerating. The guidance midpoint of $149 million is slightly below the $150 million achieved in Q4 2024, implying a YoY decline of -0.7%. This reinforces the theme of a disconnect between accelerating sales and flat-to-down profitability, driven by FX and bonus accrual headwinds.
Reversing. The tightened guidance implies a full year that is essentially flat, which would be a significant achievement after years of decline and would mark a successful stabilization of the top line.
Stable. The midpoint of $650 million represents a 2.4% increase over FY 2024's $634.8 million. While quarterly performance is choppy, the full-year outlook shows modest profit growth, indicating progress despite the headwinds.